Fei is currently the Managing Director of Boehringer Ingelheim Venture Fund USA. She joined the Boehringer Ingelheim Venture Fund in 2020 and is located in Boston, MA. She served as board member of Abexxa Biologics in Arlington. Currently, she is on the Boards of Rgenta Therapeutics in Cambridge, ArrePath in Princeton, xCures in Oakland and STRM. Bio in Cambridge.
Fei received her Ph.D. in Neuropharmacology from Loyola University Chicago Stritch School of Medicine and a B.Sc in Biochemistry from East China University Science & Technology. In 2007, she started her industrial career at Theravance Biopharma as an in vivo pharmacologist and led a lab in driving multiple research projects from exploratory, lead optimization to development candidate nomination, including TD-1473 in Ulcerative Colitis, Ampreloxetine in Fibromyalgia, Velusetrag in Gastroparesis, TD-8954 in Post-operative Gastrointestinal Dysfunction. In 2015, she joined Boehringer Ingelheim Pharmaceuticals Inc. Global Immunology and Respiratory Disease Research in Ridgefield where she started as a Laboratory Head and became the Head of in vivo Pharmacology group in 2016. From 2015 to 2020, before joining the BI Venture Fund, Fei led a group of ~20 in vivo pharmacologists supporting the Immunology and Respiratory Portfolio for small molecule, antisense and antibody projects.